Policy | July 26, 2022
Funds for R&D in drug discovery and manufacturing :PIB
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
WuXi STA opens a new large scale continuous manufacturing plant
India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21
Merck’s first microbiology application and training lab in India
With this, the company can start selling Ibuprofen in the European markets.
Company raises the annual revenue guidance from mid-teens to high teens
Dr Sai Satish, Sr. Consultant Interventional Cardiologist performs India’s first 3 successful G4-Transcatheter Edge to Edge (G4–TEER) mitral valve repairs
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies
Subscribe To Our Newsletter & Stay Updated
